Adicet Bio Inc. (ACET)
| Bid | 0.5 |
| Market Cap | 56.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | -0.69 |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 302,161 |
| Avg. Volume (20D) | 786,923 |
| Open | 0.70 |
| Previous Close | 0.72 |
| Day's Range | 0.67 - 0.72 |
| 52-Week Range | 0.67 - 2.40 |
| Beta | 1.64 |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...
Analyst Forecast
According to 7 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 781.19% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
2 months ago · businesswire.com
Adicet Bio Provides Corporate Update and Highlights Expected 2025 MilestonesREDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...